The third quarter financial results of 10x Genomics (NASDAQ: TXG) will be revealed on Tuesday 29th October 2024. This eagerly awaited announcement is slated to occur after market close, enabling investors and market participants to gain valuable insights into the company's financial performance.
According to the predictions of financial experts on Wall Street, the enterprise is expected to announce an anticipated $0.34 loss per share for the quarter. Further, the firm is poised to disclose a total revenue of $158.63 million for the period.
In the preceding quarter of the previous year, the company shared its financial results, revealing that it had loss of $0.44 per share.
Financial experts on Wall Street have shared their predictions regarding the company's annual performance, estimating a total revenue of $636.59 million. Additionally, they are expecting the company to report loss of $1.38 per share for the full year 2024.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $-0.32 | +39.6% | 153.10 M | +4.3% |
| Q1 2024 | $-0.50 | -13.6% | 141.01 M | +5.0% |
| Q4 2023 | $-0.24 | -60.0% | 183.98 M | +17.8% |
| Q3 2023 | $-0.44 | -18.9% | 153.64 M | +17.2% |
| Q2 2023 | $-0.53 | +7.0% | 146.82 M | +28.1% |
| *Growth on year-over-year basis | ||||
Additionally, The company will host a conference call with investors and analysts on 29th October 2024 at 04:30 PM eastern time to review the Q3 2024 financial results.
The previous trading day saw 10x Genomics (TXG) shares trading between $15.40 and $15.74, besides a volume of 1.09 million shares. The stock closed Friday's regular trading session at $15.49, reflecting 0.13 percent advance.